| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The FASEB Journal, Vol 3, 1637-1643, Copyright © 1989 by The Federation of American Societies for Experimental Biology
RESEARCH COMMUNICATIONS |
LL Moldawer, MA Marano, H Wei, Y Fong, ML Silen, G Kuo, KR Manogue, H Vlassara, H Cohen and A Cerami
Department of Surgery, New York Hospital, Cornell University Medical Center, New York 10021.
Chronic inflammatory diseases are often associated with decreased red blood cell (RBC) mass. The cytokines cachectin/tumor necrosis factor- alpha (TNF) and interleukin 1 (IL 1) are produced by monocytes/macrophages in response to many inflammatory stimuli and have been implicated in the anemia of chronic disease. This study was undertaken to evaluate the mechanisms by which cachectin/TNF, IL 1, or endotoxin induce anemia. Hematologic parameters and RBC kinetics were quantitated in rats given chronic sublethal quantities of either recombinant human cachectin/TNF, recombinant human IL 1 alpha, or Salmonella endotoxin for 7 days. Cachectin/TNF or endotoxin treatment resulted in a 25 or 31% decrease, respectively, in total RBC mass, whereas RBC mass was unchanged by IL 1 administration. Anemia associated with either chronic cachectin or endotoxin administration was characterized by normal mean corpuscular volume, mean corpuscular hemoglobin content, and reticulocyte numbers. [59Fe]RBC survival was significantly shortened in animals given cachectin, IL 1 or endotoxin, but the magnitude of the response was greatest in cachectin/TNF-or endotoxin-treated rats. Although cachectin/TNF-IL 1-, or endotoxin treatment resulted in similar hypoferremia and shortened plasma iron half-life, endotoxin or cachectin/TNF treatment (but not IL 1) significantly reduced the incorporation of plasma 59Fe into newly synthesized RBCs. We conclude that chronic cachectin/TNF administration produces anemia by decreasing RBC synthesis and reducing the life span of circulating RBCs. An endogenous cachectin/TNF response during inflammatory disease may contribute to an associated anemic state, whereas the modestly reduced red cell life span induced by IL 1 does not lead to a net reduction in RBC mass, presumably owing to a preserved RBC synthetic rate.
This article has been cited by other articles:
|
|
 |
|
  L. Tacchini, E. Gammella, C. De Ponti, S. Recalcati, and G. Cairo Role of HIF-1 and NF-{kappa}B Transcription Factors in the Modulation of Transferrin Receptor by Inflammatory and Anti-inflammatory Signals J. Biol. Chem., July 25, 2008; 283(30): 20674 - 20686. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. N. Roy, H. H. Mak, I. Akpan, G. Losyev, D. Zurakowski, and N. C. Andrews Hepcidin antimicrobial peptide transgenic mice exhibit features of the anemia of inflammation Blood, May 1, 2007; 109(9): 4038 - 4044. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Furuta, T. Kikuchi, Y. Iwakura, and N. Watanabe Protective Roles of Mast Cells and Mast Cell-Derived TNF in Murine Malaria. J. Immunol., September 1, 2006; 177(5): 3294 - 3302. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Theurl, V. Mattle, M. Seifert, M. Mariani, C. Marth, and G. Weiss Dysregulated monocyte iron homeostasis and erythropoietin formation in patients with anemia of chronic disease Blood, May 15, 2006; 107(10): 4142 - 4148. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Similowski, A. Agusti, W. MacNee, and B. Schonhofer The potential impact of anaemia of chronic disease in COPD Eur. Respir. J., February 1, 2006; 27(2): 390 - 396. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Wang, M. D. Garrick, F. Yang, L. A. Dailey, C. A. Piantadosi, and A. J. Ghio TNF, IFN-{gamma}, and endotoxin increase expression of DMT1 in bronchial epithelial cells Am J Physiol Lung Cell Mol Physiol, July 1, 2005; 289(1): L24 - L33. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Weiss and L. T. Goodnough Anemia of Chronic Disease N. Engl. J. Med., March 10, 2005; 352(10): 1011 - 1023. [Full Text] [PDF]
|
|
|
|
 |
|
 C Gasche, M C E Lomer, I Cavill, and G Weiss Iron, anaemia, and inflammatory bowel diseases Gut, August 1, 2004; 53(8): 1190 - 1197. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Jacobs-Helber, K.-h. Roh, D. Bailey, E. N. Dessypris, J. J. Ryan, J. Chen, A. Wickrema, D. L. Barber, P. Dent, and S. T. Sawyer Tumor necrosis factor-alpha expressed constitutively in erythroid cells or induced by erythropoietin has negative and stimulatory roles in normal erythropoiesis and erythroleukemia Blood, January 15, 2003; 101(2): 524 - 531. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Weinstein, C. N. Roy, M. D. Fleming, M. F. Loda, J. I. Wolfsdorf, and N. C. Andrews Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease Blood, November 15, 2002; 100(10): 3776 - 3781. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Yang, X.-b. Liu, M. Quinones, P. C. Melby, A. Ghio, and D. J. Haile Regulation of Reticuloendothelial Iron Transporter MTP1 (Slc11a3) by Inflammation J. Biol. Chem., October 11, 2002; 277(42): 39786 - 39791. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Mora, M. Macia, and J. F. Navarro Renal failure, anaemia, cytokines and inflammation Nephrol. Dial. Transplant., July 1, 2001; 16(7): 1524 - 1525. [Full Text] [PDF]
|
|
|
|
|
|
S. Fargion, L. Valenti, P. Dongiovanni, A. Scaccabarozzi, A. L. Fracanzani, E. Taioli, M. Mattioli, M. Sampietro, and G. Fiorelli Tumor necrosis factor {alpha} promoter polymorphisms influence the phenotypic expression of hereditary hemochromatosis Blood, June 15, 2001; 97(12): 3707 - 3712. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Silvestris, M. Tucci, P. Cafforio, and F. Dammacco Fas-L up-regulation by highly malignant myeloma plasma cells: role in the pathogenesis of anemia and disease progression Blood, March 1, 2001; 97(5): 1155 - 1164. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Brittenham, G. Weiss, P. Brissot, F. Laine, A. Guillygomarc'h, D. Guyader, R. Moirand, and Y. Deugnier Clinical Consequences of New Insights in the Pathophysiology of Disorders of Iron and Heme Metabolism Hematology, January 1, 2000; 2000(1): 39 - 50. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Kakinuma, Y. Hamada, Y. Futamura, C. Kuwayama, A. Shimoi, and Y. Shibutani Human Natural Tumor Necrosis Factor {alpha} Induces Multiple Endocrine and Hematologic Disorders in Rats Toxicol Pathol, July 1, 1999; 27(4): 402 - 411. [Abstract] [PDF]
|
|
|
|
 |
|
 N. S. Postma, R. C. Hermsen, D. J. A. Crommelin, W. M. C. Eling, and J. Zuidema Thiolated Recombinant Human Tumor Necrosis Factor-Alpha Protects against Plasmodium berghei K173-Induced Experimental Cerebral Malaria in Mice Antimicrob. Agents Chemother., May 1, 1999; 43(5): 1027 - 1033. [Abstract] [Full Text]
|
|
|
|
 |
|
 N. S. Postma, D. J. A. Crommelin, W. M. C. Eling, and J. Zuidema Treatment with Liposome-Bound Recombinant Human Tumor Necrosis Factor-alpha Suppresses Parasitemia and Protects against Plasmodium berghei k173-Induced Experimental Cerebral Malaria in Mice J. Pharmacol. Exp. Ther., January 1, 1999; 288(1): 114 - 120. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
